Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

483
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
483
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

557
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
557
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

526
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
526
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

439
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
439
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

599
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
599
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

354
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
354

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term prognostic value of microvascular obstruction by cardiac magnetic resonance in ST-segment elevation myocardial infarction.

PloS one·2026
Same author

Pre-Hospital Artificial Intelligence-Guided, Focused Echocardiography in Patients with Acute Chest Pain for Diagnosis of Acute Coronary Syndrome.

Journal of clinical medicine·2025
Same author

Assessment of infarct characteristics and left ventricular function on serial CMR in STEMI patients treated with post-PCI sonothrombolysis: post-hoc analysis of two randomized controlled trials.

International journal of cardiology. Heart & vasculature·2025
Same author

Determinants of symptom relief and quality of life improvement after atrial fibrillation ablation.

European heart journal. Quality of care & clinical outcomes·2025
Same author

Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial.

Cardiovascular research·2025
Same author

Does providing atrial fibrillation patients, after pulmonary vein isolation, with a 1-lead ECG device relieve the emergency department?-A historically controlled prospective trial.

PLOS digital health·2024

Related Experiment Video

Updated: Jan 29, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

[Hypertrophic cardiomyopathy].

Beau van Driel1,2, Folkert W Asselbergs3, Rudolf A de Boer4

  • 1Amsterdam UMC, afd. Fysiologie, locatie VUmc.

Nederlands Tijdschrift Voor Geneeskunde
|February 8, 2019
PubMed
Summary
This summary is machine-generated.

Hypertrophic cardiomyopathy (HCM) is a common genetic heart disease affecting 1:200 people. Understanding its varied clinical stages and manifestations is crucial for timely diagnosis and effective treatment of HCM patients.

More Related Videos

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Related Experiment Videos

Last Updated: Jan 29, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Area of Science:

  • Cardiology
  • Genetics

Background:

  • Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic cardiac disorder, impacting 1:200 to 1:500 individuals.
  • Defined by left ventricular hypertrophy (≥15 mm wall thickness) without secondary causes like hypertension, HCM stems from autosomal dominant mutations in cardiac sarcomere protein genes.

Observation:

  • HCM presents a wide spectrum of clinical phenotypes, from asymptomatic carriers to severe left ventricular hypertrophy.
  • Manifestations include sudden cardiac death and end-stage heart failure, even in young individuals.

Findings:

  • This study details a case of a 60-year-old female HCM patient.
  • It outlines the four clinical stages of HCM, associated complications, and current therapeutic strategies.

Implications:

  • Recognizing the diverse clinical stages and manifestations of HCM is essential for prompt patient identification.
  • Effective management and treatment initiation depend on a thorough understanding of HCM's heterogeneous presentation.